Condition
Monoclonal Gammopathy of Renal Significance (MGRS)
Total Trials
2
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
P 2 (1)
Trial Status
Not Yet Recruiting1
Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT06771180Phase 2Not Yet RecruitingPrimary
Dara-BCD for Rare MGRS
NCT05283993Recruiting
A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
Showing all 2 trials